News

Narcolepsy is a globally recognized rare disease. In Asia, the prevalence rate of this condition is 0.0129% in Taiwan and 0.015% in South Korea. The peak age of onset in China is 8-12 years old. Currently, narcolepsy faces challenges such as low public awareness, low diagnosis rate and insufficient effective treatment drugs. “Tetralogy” is a common symptom of narcolepsy, which is very disturbing to life. (Tetralogy includes excessive daytime sleepiness, cataplexy attack, hypnagogic hallucination and sleep paralysis.) On June 30, 2023, Pitolisant Hydrochloride Tablets were approved in China for the treatment of adult narcolepsy indications. On December 13, 2023, Pitolisant Hydrochloride Tablets in two formulations were successfully included in the 2023 National Medical Insurance Negotiation Drug List. Pitolisant Hydrochloride Tablets are the world’s first H3 receptor antagonist/inverse agonist that increases the synthesis and release of the wakefulness-promoting neurotransmitter histamine in the brain by enhancing histaminergic neuron activity, thereby improving wakefulness and alertness in patients. From December 2023 to January 2024, the “Awakening Dreams, Creating the Future – Expert Consultation on Pitolisant Hydrochloride Tablets for Narcolepsy” was held in Guangzhou, Beijing and Shanghai. Renowned professors and experts from major hospitals in China participated, discussing guidelines interpretation, disease recognition, drug treatment and

To enhance the diagnosis and treatment of narcolepsy, promote exchanges and cooperation among medical units of provincial sleep coordination groups, and strengthen the construction of professional team of sleep disorders in sleep centers, HSN organized two special academic salons on narcolepsy in January 2024, covering more than 200 sleep experts from Shaanxi, Heilongjiang, Jilin and Liaoning provinces. The meeting of the provincial sleep collaboration group for the three northeastern provinces was held on January 26 via Tencent Meeting, with over 70 participants. Yang Yi, Vice President (Deputy Secretary) of the First Bethune Hospital of Jilin University, delivered the opening speech, and Professor Wang Zan chaired the meeting and lectured on Identification and Treatment of Narcolepsy, emphasizing the need of the disease for long-term medication, the disease’s threat to life safety, learning ability, economic burden and employment. He also pointed out low public awareness rate, long diagnosis time, and differential diagnosis of combined diseases. Through research, he shared the relieving effect of Pitolisant on tetralogy, and looked forward to the launch of Pitolisant. Professor Zhu Yulan from the 2nd Affiliated Hospital of Harbin Medical University explained the Interpretation of China’s Narcolepsy Guidelines 2022, emphasizing the first-tier recommendation status of Pitolisant. Professor